Quote:
Originally Posted by nbritton
That's because it's not a single disease. They need to drill down on the different clinical presentations of the illness to get useable data. The DSM 5 completely eliminated subtypes, which I think is a backwards step.
Instead of focusing on global symptom groups, they need to focus on medication groups. For instance, all those that respond exceptionally well to Latuda should be grouped together and then studied at the genetic and symptomology level. Rinse and repeat for each major medication until trends emerge.
|
I agree...the problem is this stuff isn't being done by the pdocs they don't seem to have great academic medicine departments. The genome studies never seem to correlate med response...all you need is a survey for the sequenced patients meds that worked well side effects etc...legally you'd probably need a psychologist to design it to get past an IRB but it's so easy...
The closest I've seen to this is 23 and me...they basically were investigating several types of drugs and APs were one...the problem was a very low sample of people with sz...it would work so much better if people with actual patient access did these studies along with the genetic experts...